JXR(01951) Shenzhen Zhongshan Maternity Hospital's new hospital trial operation, the number of egg retrieval cycles in the first two months increased by 18% compared with the previous year, and increased by about 38% compared with the United States.

JXR (01951) announced that the new campus of Shenzhen Zhongshan Maternity and Child Health Hospital, a subsidiary of the group, will begin trial operation from February 6, 2026. The new campus is located in the central area of Shenzhen, with a total construction area of 40,000 square meters, approximately four times the size of the original campus. The use of the new campus has laid a solid foundation for the continued development of the business of Shenzhen Zhongshan Maternity and Child Health Hospital, and has also effectively promoted the hospital's expansion into VIP services, specialty departments, and special services such as the international medical department. With the opening of the new campus, the group's business in Shenzhen has maintained strong growth momentum, with a 18% increase in Ovum Pick-Up (OPU) cycles in the first two months of 2026 compared to the same period in 2025. In the United States, HRC Fertility clinics under the group's management service agreement increased OPU cycles by approximately 38% in the first two months of 2026 compared to the same period in 2025. This growth is mainly due to an increase in demand from local patients following the formal implementation of in vitro fertilization (IVF) insurance coverage under California Senate Bill 729 (SB729) since January 2026. The law was originally scheduled to take effect around July 2025 but was later postponed. Under SB729, large employers with over 100 employees must provide coverage for the diagnosis and treatment of infertility, while small and medium-sized enterprises can voluntarily choose to participate. The coverage includes three complete OPU cycles and unlimited embryo transfer cycles, without any differentiation based on marital status or other conditions. The company will continue to promote operational optimization, improve clinical efficacy, focus on enhancing patient care and service quality, and accelerate the research and upgrading of core reproductive technologies. Through these measures, the company is committed to creating long-term sustainable value for shareholders and promoting the high-quality development of the industry.